Background Image


INFEX Therapeutics Logo

INFEX Therapeutics

Industry Sector


Deal Type

Early Growth



Based at Alderley Park, INFEX Therapeutics aims to tackle the urgent global threat from antimicrobial resistance, which left untreated, will kill an extra 10m patients per year – more deaths than cancer.  It helps accelerate the development of new antibiotics by providing development services to companies around the world in return for a commercial share from new products developed.

In 2020 it expanded its portfolio to tackle a wider array of infectious diseases, developing lifesaving antibacterial and antiviral therapies.

Why we like the business

Anti-microbial resistance is now recognised as a threat to humanity and INFEX is a key part of the UK’s response to this global threat. INFEX is a founder partner of CARB-X, a US-based anti-microbial grant funder which is investing $455m into suitable projects around the world. The costs of its unique development capabilities are significantly reduced thanks to CARB-X grants, while the scientific risks are reduced through access to the CARB-X panel of world leading experts.